13D Filings

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Zenas BioPharma Grants 11,000 RSUs to Newly Hired Employees Under 2026 Inducement Plan

Zenas Biopharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma reports Q2 EPS ($1.77), consensus (75c)

Zenas BioPharma CFO Jennifer Fox to transition out of role

Zenas BioPharma Price Target Maintained with a $45.00/Share by Wedbush

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma, Inc. (ZBIO) Receives a Buy from Guggenheim

Analysts Offer Insights on Healthcare Companies: MDxHealth (MDXH), Opko Health (OPK) and Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Searches for CFO as Fox Transitions to Advisory Role

Zenas BioPharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate

Zenas Biopharma Posts Corporate Presentation on Autoimmune Disease Pipeline, Led by Obexelimab Program

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss

Zenas BioPharma Q2 FY26 Net Loss Widens to $111.5 Million; Revenue Rises to $1 Million

Zenas Biopharma, Inc.: Qtrly EPS $-1.77

Press Release: Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments